65,437 trials
De Novo Kidney Transplantation
Primary: Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review — 6.7; 10.6 percentage of participants
Smoking Cessation
Primary: 7-day Point Prevalence Smoking Abstinence With Cotinine Validation at the End of Treatment — 0; 2 participants
Cerebral Palsy
Primary: Walking Activity Levels — 4660; 4897 average total strides/day — p=< 0.05
Gastroparesis · Diabetes Mellitus
Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002
Knee Osteoarthritis
Primary: Change in Isotonic Leg Press 1RM — 4.7; 3.1 percent change
Hepatitis C
Primary: Mean Change From Baseline in HCV Viral Load — -0.42; -1.88; -3.39 Log10 change
Autism · Pervasive Development Disorder · Asperger's Disorder
Primary: Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents — 45.2; 46.9; 29.0; 19.4 percentage of participants — p=0.47
Pregnancy
Primary: Percentage of Total Fatty Acids by Weight — 4.7; 7.3; 4.8; 7.8 percentage of fatty acid
Preterm Labour
Primary: Uterine Natural Killer Cells In Preterm Labor — 21; 1; 0; 0 participants — p=<0.0002
Healthy Subjects
Primary: Description of the Safety Profile in Terms of Adverse Events (AE),Vital Signs, ECG, Lab Variables, Immunogenicity and Physical Examination — 2; 3; 2; 1 Participants
TNF-receptor Associated Periodic Syndromes (TRAPS)
Primary: Percentage of Participants With Complete or Almost Complete Response at Day 15 — 95 Percentage of participants
Colorectal Cancer
Primary: Progression-free Survival — 15.4 months
Cardiac Arrhythmias · Heart Failure
Primary: Heart Failure Clinical Composite Score — 551; 559; 76; 86 participants
Psoriatic Arthritis
Primary: Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo — 50.5; 50.0; 17.3 % participant — p=<0.0001
Major Depressive Disorder
Primary: Number of Participants Who Tolerated Brexpiprazole — 6; 7; 5 participants